Evaluation of the effectiveness of Berberis integerrima and Thyme essential oil in the treatment of acne

Evaluation of the effectiveness of the combination of Berberis integerrima root extract and Thyme essential oil in the treatment of acne vulgaris Compared to clindamycin

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150721023282N21

Enrollment

Registered

2021-11-07

Start date

2021-12-21

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris. L70.0

Interventions

Intervention 1: Intervention group: 5% Berberis integerrima extract and 1% thyme essential oil in 70% ethanol topical solution, made by Isfahan University of Medical Science, School of Pharmacy, for 2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Mild acne vulgaris. Mild acne is defined as non-inflammatory lesions (comedones), a few inflammatory (papulopustular) lesions, without nodules and cysts. Moderate acne vulgaris. Moderate acne is defined as more inflammatory lesions, with or without comedones, without nodules and cysts.

Exclusion criteria

Exclusion criteria: Receiving systemic anti-acne treatment during last three months Receiving oral anti-acne treatment during last one month Receiving systemic antibiotics during last one month Receiving antiandrogen medicine during last three months Hepatic or renal disorder Endocrine disorders Receiving oral contraceptive during last one month Other skin disorders or infection Pregnancy Lactation Consumption of any drugs that induce acne Alcohol or substance abuse

Design outcomes

Primary

Measure	Time frame
Percentage change in mGAGS scale at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Visio Face - Camera.;Change the number of lesions at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Visio Face - Camera.;Change of the number of lesions based on the type of lesion at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Visio Face - Camera.	—

Measure

Time frame

Percentage change in mGAGS scale at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Visio Face - Camera.;Change the number of lesions at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Visio Face - Camera.;Change of the number of lesions based on the type of lesion at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Visio Face - Camera.

—

Secondary

Measure	Time frame
Number of people with complete recovery at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Observation.;Time required for complete recovery. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRasool Soltani

Esfahan University of Medical Sciences

soltani@pharm.mui.ac.ir0098 31 3792706

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026